Toxocara and Toxocariasis

PART I - The organism and the recognition of the disease<br>1. Toxocara: Protecting pets and improving the lives of people<br>2. History of Toxocara and the associated larva migrans<br>3. The anatomy of the third-stage larva of Toxocara canis and Toxocara cati<br>4. Visceral larval migrans of Toxocara canis and Toxocara cati in non-canid and non-felid hosts<br>5. Toxocara “omics” and the promises it holds for medicine and veterinary medicine<br>PART II - The effects of infection, host response to infection, diagnosis, and treatment of people<br>6. Toxocariasis and the clinical spectrum<br>7. Serodiagnostic methods for diagnosing larval toxocariasis<br>8. Clinical pathology of larval toxocariasis<br>9. Imaging of toxocariasis<br>10. Toxocara-induced neural larva migrans (neurotoxocarosis) in rodent model hosts<br>11. Neurotoxocariasis<br>12. Pathogenesis of cerebral toxocariasis and neurodegenerative diseases<br>13. Neurocognitive and neuropsychiatric effects of toxocariasis<br>PART III – Epidemiology<br>14. Global and regional seroprevalence estimates for human toxocariasis: A call for action<br>15. Toxocara seroprevalence in Canada—Climate, environment and culture<br>16. Toxocara seroprevalence in the USA and its impact for individuals and society<br>17. Toxocara: Seroprevalence in Mexico<br>18. Seroprevalence Brazil<br>19. Seroprevalence of human toxocarosis in Europe: A review and meta-analysis<br>20. Seroprevalence and incidence of human toxocarosis in Russia<br>21. Current epidemic situation of human toxocariasis in China<br>22. Seroprevalence of Toxocara spp. infection in Southeast Asia and Taiwan<br>23. Sources and seroprevalence of toxocariasis in Turkey<br>24. Seroprevalence of Toxocara spp. antibodies in humans in Africa: A review<br>25. Seroepidemiology of human toxocariasis in North Africa<br>PART IV - Dogs (and cats) disease, diagnosis, prevalence of infection, and treatment<br>26. Pathology of larvae and adults in dogs and cats<br>27. Antigen detection: Insights into Toxocara and other ascarid infections in dogs and cats<br>28. Global prevalence of Toxocara infection in dogs<br>29. Sources of environmental contamination with Toxocara spp.: An omnipresent parasite<br>30. Global prevalence of Toxocara infection in cats<br>31. Toxocara spp. in dogs and cats in Canada<br>32. Toxocara canis and Toxocara cati in domestic dogs and cats in the United States, Mexico, Central America and the Caribbean: A review<br>33. Toxocara prevalence in dogs and cats in Brazil<br>34. Prevalence of Toxocara spp. in dogs and cats in South America (excluding Brazil)<br>35. Prevalence of patent Toxocara spp. infections in dogs and cats in Europe from 1994 to 2019<br>36. Toxocara prevalence in dogs, cats and the environment in Russia<br>37. Canine Toxocariosis: Its prevalence, incidence and occurrence in the Indian subcontinent<br>38. Epidemiology of Toxocara spp. in dogs and cats in mainland China, 2000–2019<br>39. Prevalence of Toxocara in dogs and cats in Africa<br>40. Toxocara canis in Australia<br>41. Toxocariasis: A neglected infection for the Anthropocene epoch